Objective: The cancer stem-like cells (CSC) CSC markers and the role derived from papillary thyroid carcinoma (PTC) in the pathogenesis is unclear. This study aims to determine the nature of CSC using a ball tumor cells passaged but without sorting PTC CSC.
Materials and Methods: To identify the properties of CSC derived from PTC, the expression of SRY-box transcription factor 2 (Sox2), octamer – bind transcription factor 4 (OCT 4 ), Nanog homeobox (NANOG), thyroglobulin (TG), thyroid-stimulating hormone receptor (TSHR), E-cadherin, YES-related protein 1 (YAP1), and signal transducer and activator transcription < / em> 3 (STAT3) was investigated in the field of serial tumor passaged without sorting CSC.
Results: Ball cultured tumor had cancer stemness; High expression of October 4 , Sox2, NANOG, and YAP1; Low expression of E-cadherin; and varied expression of TG, TSHR, and STAT3. PTC tumors ball transfected with small interfering RNA targeting YAP1 possess less of the ball CSC non-transfected tumors are doing.
Conclusions: Tumor sphere cells derived from PTC by passaging without sorting CSC has more stem cell-like properties, and less differentiation potential. Thus, a simple and cost-effective method can be used for enrichment PTC stemness to work in cell-based models, reducing the need for the use of animal models. Impact OCT4 and Its Related Signaling Pathways in Cancer Gastrointestinal: Focused on Targeted Therapies There are many pieces of evidence support the effects of cancer stem cells in the initiation and progression of cancer.

However, the related mechanisms involved in this phenomenon is much more complicated to understand. Stemness different functions factor in the cancer stem cells (CSC) and their complex associations at different levels of cancer have been reported. Therefore, it seems that the focus on a single master factor will be more helpful to solve the puzzle singling pathway in these cells. Octamer – bind transcription factor 4 (OCT 4 ) is also known as POU domain, class 5, transcription factor 1 (POU5F1), one of these pluripotency the factor , has an important role in both embryogenesis and tumorigenesis.
In this review, we collect information about the relationship of different markers to October 4 of expression in the three types of gastrointestinal cancers including esophageal, gastric and colorectal cancers. October 4 via different signaling pathways have an impact on different processes of gastrointestinal cancers such as proliferation, invasion, and metastasis. Based on the literature, Oct. 4 have a profound effect on the development of cancer at different stages, therefore we suggest it has potential implications in the choice of therapy.
Although the pharmacological action of cardiovascular Tanshinone IIA (TanIIA) have been extensively studied, research on the role in the regeneration of the heart is still sufficient. This study used H9c2 heart myoblast cell line to evaluate the possibility TanIIA role in cardiac regeneration. It was found that certain concentrations of TanIIA inhibited cell proliferation by suppressing the expression of proteins associated with cell cycle [cyclin dependent kinase (CDK) 4 , CDK6 and cyclin D1] and proliferation [c-Myc, octamer – bind transcription factor 4 (October 4 ) and growing multiply cell nuclear antigen (PCNA)] without inducing apoptosis.
Lin28 Antibody |
|||
25055-100ul | SAB | 100ul | EUR 468 |
Lin28 Antibody |
|||
21426-100ul | SAB | 100ul | EUR 302.4 |
Lin28 Antibody |
|||
21426-50ul | SAB | 50ul | EUR 224.4 |
Lin28 antibody |
|||
3091-200 | Biovision | each | EUR 379.2 |
Lin28 antibody |
|||
3091-30T | Biovision | each | EUR 175.2 |
LIN28 Antibody |
|||
BF0638 | Affbiotech | 200ul | EUR 540 |
Lin28 antibody |
|||
70R-11606 | Fitzgerald | 200 ug | EUR 483.6 |
Description: Rabbit polyclonal Lin28 antibody |
Lin28 Antibody |
|||
5605-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: Lin28 Antibody: Lin28 is a transcription factor that was first identified through its key role in the pathway of developmental timing in C. elegans. The role of Lin28 in development suggested that it might be useful in the creation of stem cells that might be beneficial in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing Lin28 in addition to the transcription factors POU5F1, Sox2, and NANOG in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing Lin28, Sox2, POU5F1 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine. |
Lin28 Antibody |
|||
5605-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: Lin28 Antibody: Lin28 is a transcription factor that was first identified through its key role in the pathway of developmental timing in C. elegans. The role of Lin28 in development suggested that it might be useful in the creation of stem cells that might be beneficial in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing Lin28 in addition to the transcription factors POU5F1, Sox2, and NANOG in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing Lin28, Sox2, POU5F1 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine. |
Lin28 Antibody |
|||
49538-100ul | SAB | 100ul | EUR 399.6 |
Lin28 Antibody |
|||
49538-50ul | SAB | 50ul | EUR 286.8 |
LIN28 antibody |
|||
70R-18278 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal LIN28 antibody |
LIN28 Antibody |
|||
F41528-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
Description: Acts as a 'translational enhancer', driving specific mRNAs to polysomes and thus increasing the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in stabilizing the mRNAs. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression (By similarity). Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Degradation of pre-let-7 in embryonic stem (ES) cells contributes to the maintenance of ES cells. In contrast, LIN28A down-regulation in neural stem cells by miR-125, allows the processing of pre-let-7. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. |
LIN28 Antibody |
|||
F41528-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
Description: Acts as a 'translational enhancer', driving specific mRNAs to polysomes and thus increasing the efficiency of protein synthesis. Its association with the translational machinery and target mRNAs results in an increased number of initiation events per molecule of mRNA and, indirectly, in stabilizing the mRNAs. Binds IGF2 mRNA, MYOD1 mRNA, ARBP/36B4 ribosomal protein mRNA and its own mRNA. Essential for skeletal muscle differentiation program through the translational up-regulation of IGF2 expression (By similarity). Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Degradation of pre-let-7 in embryonic stem (ES) cells contributes to the maintenance of ES cells. In contrast, LIN28A down-regulation in neural stem cells by miR-125, allows the processing of pre-let-7. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. |
LIN28 Antibody |
|||
E306153 | EnoGene | 100ug/200ul | EUR 275 |
Description: Available in various conjugation types. |
LIN28 Antibody |
|||
E10-20271 | EnoGene | 100μg/100μl | EUR 225 |
Description: Available in various conjugation types. |
Lin28 Antibody |
|||
E021426 | EnoGene | 100μg/100μl | EUR 170 |
Description: Available in various conjugation types. |
LIN28 Antibody |
|||
E2200808 | EnoGene | 100ug | EUR 255 |
Description: Available in various conjugation types. |
Lin28 Antibody [1G9H9] |
|||
PM-6143-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: Lin28 Monoclonal Antibody: Lin28 is a transcription factor that was first identified through its key role in the pathway of developmental timing in C. elegans. The role of Lin28 in development suggested that it might be useful in the creation of stem cells that might be beneficial in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing Lin28 in addition to the transcription factors POU5F1, Sox2, and NANOG in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing Lin28, Sox2, POU5F1 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine. |
Lin28 Antibody [1G9H9] |
|||
PM-6143-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: Lin28 Monoclonal Antibody: Lin28 is a transcription factor that was first identified through its key role in the pathway of developmental timing in C. elegans. The role of Lin28 in development suggested that it might be useful in the creation of stem cells that might be beneficial in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing Lin28 in addition to the transcription factors POU5F1, Sox2, and NANOG in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing Lin28, Sox2, POU5F1 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine. |
LIN28 (pS134) Antibody |
|||
abx032091-400ul | Abbexa | 400 ul | EUR 627.6 |
LIN28 (pS134) Antibody |
|||
abx032091-80l | Abbexa | 80 µl | EUR 343.2 |
Polyclonal Lin28 Antibody |
|||
AMM06296G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Lin28 . This antibody is tested and proven to work in the following applications: |
Polyclonal LIN28 Antibody |
|||
AMM06297G | Leading Biology | 0.1ml | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIN28 . This antibody is tested and proven to work in the following applications: |
Lin28 Conjugated Antibody |
|||
C49538 | SAB | 100ul | EUR 476.4 |
Lin28 Conjugated Antibody |
|||
C21426 | SAB | 100ul | EUR 476.4 |
LIN28 Polyclonal Antibody |
|||
E96034 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
LIN28 Antibody (phospho-S134) |
|||
F48636-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 140.25 |
Description: LIN28 is probable transcription factor. It plays a critical role in the control of immune response. |
LIN37 Antibody (FITC) |
|||
20-abx309143 | Abbexa |
|
|
Monoclonal LIN28 Antibody, Clone: 6D1F9 |
|||
AMM02686G | Leading Biology | 0.1ml | EUR 633.6 |
Description: A Monoclonal antibody against Human LIN28. The antibodies are raised in Mouse and are from clone 6D1F9. This antibody is applicable in WB, ICC, E |
Anti-LIN28 antibody |
|||
PAab04783 | Lifescience Market | 100 ug | EUR 426 |
LIN37 Antibody, FITC conjugated |
|||
1-CSB-PA836222LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LIN37. Recognizes LIN37 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
Polyclonal LIN28A / LIN28 Antibody (C-Terminus) |
|||
AMM06299G | Leading Biology | 0.05mg | EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIN28A / LIN28 (C-Terminus). This antibody is tested and proven to work in the following applications: |
LIN9 Antibody, FITC conjugated |
|||
1-CSB-PA716370LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LIN9. Recognizes LIN9 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
LIN28A Antibody, FITC conjugated |
|||
1-CSB-PA13619C0Rb | Cusabio |
|
|
Description: A polyclonal antibody against LIN28A. Recognizes LIN28A from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
LIN28B Antibody, FITC conjugated |
|||
1-CSB-PA741049LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LIN28B. Recognizes LIN28B from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
Monoclonal Lin28 Antibody [1G9H9] , Clone: 1G9H9 |
|||
AMM06298G | Leading Biology | 0.1 mg | EUR 790.8 |
Description: A Monoclonal antibody against Human Lin28 [1G9H9] . The antibodies are raised in Mouse and are from clone 1G9H9. This antibody is applicable in WB, E |
Protein Lin-28 Homolog A (LIN28) Antibody |
|||
abx234783-100ug | Abbexa | 100 ug | EUR 577.2 |
Protein Lin-28 Homolog A (LIN28) Antibody |
|||
abx026317-400ul | Abbexa | 400 ul | EUR 627.6 |
Protein Lin-28 Homolog A (LIN28) Antibody |
|||
abx026317-80l | Abbexa | 80 µl | EUR 343.2 |
Protein Lin-28 Homolog A (LIN28) Antibody |
|||
abx036687-100ug | Abbexa | 100 ug | EUR 469.2 |
Protein Lin-28 Homolog A (LIN28) Antibody |
|||
abx011091-100ul | Abbexa | 100 ul | EUR 493.2 |
LIN7A Antibody, FITC conjugated |
|||
1-CSB-PA012963LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LIN7A. Recognizes LIN7A from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
LINC00846 Antibody (FITC) |
|||
20-abx311644 | Abbexa |
|
|
LINC00299 Antibody (FITC) |
|||
20-abx314552 | Abbexa |
|
|
LINC01553 Antibody (FITC) |
|||
20-abx303234 | Abbexa |
|
|
Anti-Noelin Antibody FITC Antibody FITC |
|||
STJ501939 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Noelin Antibody FITC Antibody FITC |
|||
STJ501941 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LIN28 Monoclonal Antibody |
|||
M01966-1 | BosterBio | 100ug | EUR 476.4 |
Description: Rabbit Monoclonal LIN28 Antibody. Validated in IP, IF, WB and tested in Human. |
Lin-28 Homolog B (LIN28B) Antibody (FITC) |
|||
20-abx315062 | Abbexa |
|
|
Lin-28 Homolog A (LIN28A) Antibody (FITC) |
|||
20-abx337280 | Abbexa |
|
|
LIN37 Polyclonal Antibody, FITC Conjugated |
|||
A59632 | EpiGentek |
|
|
Anti-CCK-BR antibody |
|||
STJ92073 | St John's Laboratory | 200 µl | EUR 236.4 |
Description: Rabbit polyclonal to CCK-BR. |
LIN7A Polyclonal Antibody, FITC Conjugated |
|||
A62876 | EpiGentek |
|
|
Protein Lin-7 Homolog A (LIN7A) Antibody (FITC) |
|||
20-abx304363 | Abbexa |
|
|
Anti-Lin28 Antibody [JA10-63] |
|||
ET1704-26 | HUABIO | 100ul | EUR 231 |
Description: LIN-28 is a highly conserved, RNA-binding, cytoplasmic protein. It consists of a cold shock domain and retroviral-type (CCHC) zinc finger motifs that were first identified in Caenorhabditis elegans. LIN-28 controls the timing of events during embryonic development and is readily expressed in embryos, embryonic stem cells and embryonal carcinoma cells. The presence of LIN-28 persists in some adult tissues including cardiac and skeletal muscle. In differentiating myoblasts, LIN-28 increases protein sysnthesis efficiency and binds to the growth and differentiation factor IGF-II. |
Lin28 |
|||
E8ET1704-26 | EnoGene | 100ul | EUR 275 |
Description: Available in various conjugation types. |
LIN28 |
|||
pro-743 | ProSpec Tany | 2µg | EUR 60 |
Description: Recombinant Human LIN28 |
Human LIN7C AssayLite Antibody (FITC Conjugate) |
|||
33386-05141 | AssayPro | 150 ug | EUR 513.6 |
LINC00846 Antibody, FITC conjugated |
|||
1-CSB-PA882112LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LINC00846. Recognizes LINC00846 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
LINC00299 Antibody, FITC conjugated |
|||
1-CSB-PA765077LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LINC00299. Recognizes LINC00299 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
LINC01553 Antibody, FITC conjugated |
|||
1-CSB-PA002950LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against LINC01553. Recognizes LINC01553 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
Anti-Lin28 Rabbit Monoclonal Antibody |
|||
M01966 | BosterBio | 100ug/vial | EUR 476.4 |
Description: Rabbit Monoclonal Lin28 Antibody. Validated in IP, WB and tested in Human. |
Anti-B19 Antibody FITC |
|||
STJ501376 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Brk Antibody FITC |
|||
STJ502713 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BLK Antibody (FITC) |
|||
STJ500260 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BTK Antibody (FITC) |
|||
STJ500305 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MB Antibody (FITC) |
|||
STJ501833 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BCL6 Antibody (FITC) |
|||
STJ500222 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BCL6 Antibody (FITC) |
|||
STJ500225 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BCL6 Antibody (FITC) |
|||
STJ500228 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BCL6 Antibody (FITC) |
|||
STJ500230 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BMP1 Antibody (FITC) |
|||
STJ500267 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BMP1 Antibody (FITC) |
|||
STJ500269 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BMP2 Antibody FITC |
|||
STJ500274 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BMP4 Antibody FITC |
|||
STJ500276 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BRAF Antibody (FITC) |
|||
STJ500284 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BST1 Antibody (FITC) |
|||
STJ500287 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BST2 Antibody (FITC) |
|||
STJ500292 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BST2 Antibody (FITC) |
|||
STJ500294 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BST2 Antibody (FITC) |
|||
STJ500296 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-PGR Antibody (FITC) |
|||
STJ502477 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-PGR Antibody (FITC) |
|||
STJ502479 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-PRL Antibody (FITC) |
|||
STJ502657 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-PRL Antibody (FITC) |
|||
STJ502659 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-VHL Antibody (FITC) |
|||
STJ502737 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SFN Antibody (FITC) |
|||
STJ502962 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SHC Antibody FITC |
|||
STJ503001 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SYK Antibody (FITC) |
|||
STJ503184 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SYP Antibody (FITC) |
|||
STJ503188 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SYP Antibody (FITC) |
|||
STJ503190 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SRC Antibody (FITC) |
|||
STJ503203 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-SRC Antibody (FITC) |
|||
STJ503205 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-TEK Antibody (FITC) |
|||
STJ503260 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-TEK Antibody (FITC) |
|||
STJ503262 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-trp Antibody FITC |
|||
STJ503410 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-AFP Antibody (FITC) |
|||
STJ500053 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-AGE Antibody FITC |
|||
STJ500056 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-AQR Antibody (FITC) |
|||
STJ500152 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-Axl Antibody FITC |
|||
STJ500200 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-C4A Antibody (FITC) |
|||
STJ500329 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CD2 Antibody (FITC) |
|||
STJ500438 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CD2 Antibody (FITC) |
|||
STJ500440 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CR2 Antibody (FITC) |
|||
STJ500444 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CR2 Antibody (FITC) |
|||
STJ500446 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CD4 Antibody (FITC) |
|||
STJ500471 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CD4 Antibody (FITC) |
|||
STJ500473 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-KIT Antibody (FITC) |
|||
STJ500566 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-KIT Antibody (FITC) |
|||
STJ500569 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-KIT Antibody (FITC) |
|||
STJ500571 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-KIT Antibody (FITC) |
|||
STJ500573 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-KIT Antibody (FITC) |
|||
STJ500575 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MYC Antibody (FITC) |
|||
STJ500594 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MYC Antibody (FITC) |
|||
STJ500596 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-DCC Antibody (FITC) |
|||
STJ500740 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-DCK Antibody FITC |
|||
STJ500743 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-DEK Antibody (FITC) |
|||
STJ500752 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-ERG Antibody (FITC) |
|||
STJ500951 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-ERG Antibody (FITC) |
|||
STJ500953 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-FGR Antibody (FITC) |
|||
STJ501048 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-FSH Antibody FITC |
|||
STJ501090 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-FYN Antibody (FITC) |
|||
STJ501111 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-GFP Antibody FITC |
|||
STJ501150 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-GBA Antibody (FITC) |
|||
STJ501180 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LTF Antibody (FITC) |
|||
STJ501355 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LTF Antibody (FITC) |
|||
STJ501357 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-ILK Antibody (FITC) |
|||
STJ501451 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-ITK Antibody (FITC) |
|||
STJ501511 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LCT Antibody FITC |
|||
STJ501566 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LAT Antibody (FITC) |
|||
STJ501581 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LCK Antibody (FITC) |
|||
STJ501587 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-LYN Antibody (FITC) |
|||
STJ501641 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MPO Antibody (FITC) |
|||
STJ501783 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MPO Antibody (FITC) |
|||
STJ501785 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MPO Antibody (FITC) |
|||
STJ501787 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MPO Antibody (FITC) |
|||
STJ501789 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MPO Antibody (FITC) |
|||
STJ501791 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501902 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501904 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501906 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501908 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501910 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501912 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-MME Antibody (FITC) |
|||
STJ501914 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-OGT Antibody (FITC) |
|||
STJ502001 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-CD3 antibody (FITC) |
|||
STJ97919 | St John's Laboratory | 100 µl | EUR 280.8 |
Description: Mouse monoclonal to CD3 (FITC). |
Anti-CD4 antibody (FITC) |
|||
STJ97927 | St John's Laboratory | 100 µl | EUR 280.8 |
Description: Mouse monoclonal to CD4 (FITC). |
Anti-CD8 antibody (FITC) |
|||
STJ97937 | St John's Laboratory | 100 µl | EUR 280.8 |
Description: Mouse monoclonal to CD8 (FITC). |
Anti-5HT1A Antibody FITC |
|||
STJ500002 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-5HT1B Antibody FITC |
|||
STJ500005 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BIRC5 Antibody (FITC) |
|||
STJ503166 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BACE2 Antibody (FITC) |
|||
STJ500210 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BACE2 Antibody (FITC) |
|||
STJ500212 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BCKDK Antibody (FITC) |
|||
STJ500215 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST1 Antibody (FITC) |
|||
STJ500240 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST1 Antibody (FITC) |
|||
STJ500242 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST1 Antibody (FITC) |
|||
STJ500244 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST3 Antibody (FITC) |
|||
STJ500250 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST4 Antibody (FITC) |
|||
STJ500252 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BEST4 Antibody (FITC) |
|||
STJ500254 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-BMP8B Antibody (FITC) |
|||
STJ500278 | St John's Laboratory | 100 µg | EUR 703.2 |
In this process, the expression of cardiac troponin in the treated cells was significantly increased and the migration of cells to the wound area to be treated is significantly improved.